The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Slide banner

KEAP1-NRF2 Inhibitor (BAY 3605349)*

See how this compound is being investigated across Bayer’s oncology pipeline

Explore the tumor types, areas of research, and clinical trials associated with this investigational compound.

KEAP-1-BAY-3605349_sqrt

Compound Overview

KEAP1 functions as an E3 ligase responsible for stabilizing nuclear factor erythroid 2–related factor 2 (NRF2), a transcription factor that modulates the expression of genes involved in antioxidant, detoxification, and cytoprotective roles.1 Gain-of-function mutations in NRF2 or loss-of-function mutations in KEAP1 can promote malignant tumor growth and resistance to many standard-of-care therapies.2

KEAP1-NRF2 inhibitor (BAY 3605349)*† is a selective, small-molecule activator of KEAP1 that allosterically enhances the ability of this E3 ligase to degrade its natural cellular target, NRF2.1,3 KEAP1-NRF2 inhibitor (BAY 3605349) is currently being evaluated in a phase I clinical trial enrolling patients with advanced solid tumors.4

*Previously known as VVD-130037.
†Managed by Vividion Therapeutics.

Tumor Types

Head and neck cancer
Lung cancer
Solid tumors

Area of Research

KEAP1 signaling

Clinical Trial

Tumor Type(s)

Phase

Status

Description

NCT Number

Lung Cancer, Solid Tumors, Head and Neck Cancer

I

Now Enrolling

A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors

NCT05954312

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.